AM-1220
A synthetic CB1 agonist, Ki of 2.4 nM at human CB1. Harm reduction, not a product.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₂₆H₂₆N₂O
CAS 137642-54-7
- Family
- Synthetic CB receptor agonistNew psychoactive substance
- Molar mass
- 382.50 g/mol
Updated on
In plain terms
AM-1220 is not a hemp cannabinoid: it is a laboratory molecule, described in 1996 by pharmaceutical chemists, which binds to the same receptors as THC, with a stronger affinity in the published assays. It was identified in 2012 in products sold online and in Japan, then in dried plants onto which it had been sprayed, sold as "legal herb", often under another label. It is not a consumer product: no clinical study has evaluated its effects or its safety in human beings.
Receptors and activity
Target network
- Activates
- Binds or modulates
The lower the cited value, the closer the target sits to AM-1220: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of AM-1220.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1AgonistKi = 2.4 nM · human77 out of 100
Marusich et al. 2018, Neuropharmacology (new tab) · [3H]CP55,940 displacement, recombinant human CB1; EC50 44.4 nM in [35S]GTPγS (Emax 131.5%)
- CB2Binding (function not established)Ki = 0.3 nM · human93 out of 100
Marusich et al. 2018, Neuropharmacology (new tab) · [3H]CP55,940 displacement, recombinant human CB2; [35S]GTPγS stimulation not determinable
- TRPV1Agonistno measured value cited
Significant activation of the TRPV1 channel at a concentration producing the maximal effect at CB1; one of only three synthetic agonists tested in this case (Andersen et al., Eur J Pharmacol 2021); no EC50 value published
Pharmacology
AM-1220 belongs to the aminoalkylindoles, naphthoylindole subfamily: an indole nucleus bearing a naphthalene-1-carbonyl group at position 3 and a (1-methylpiperidin-2-yl)methyl group on the nitrogen. Marusich et al. (Neuropharmacology 2018) measure an affinity Ki = 2.40 nM at the human CB1 receptor, with an EC50 of 44.4 nM in stimulation of [35S]GTPγS; Δ9-THC appears there with a Ki of 40.7 nM, a value from Showalter et al. (1996) reproduced in the table, a ratio of about seventeen. In mice, AM-1220 fully substitutes for THC in drug discrimination, with a median effective dose of 0.26 µmol/kg against 4.96 µmol/kg for THC, a potency about nineteen times higher. In the same [35S]GTPγS assay, its maximal response at CB1 (131.5%) is lower than that of the reference CP55,940 (163.3%): the study therefore does not allow the molecule to be classed as a partial or full agonist. The CB2 profile is atypical: sub-nanomolar affinity (Ki = 0.26 nM) without measurable stimulation of [35S]GTPγS through CB2. Andersen et al. (Eur J Pharmacol 2021) add a target outside the cannabinoid system: at a concentration maximal for CB1, AM-1220 is one of only three synthetic agonists tested to significantly activate the TRPV1 channel. Beyond these in vitro measurements and the animal model, human data are lacking: no controlled study, no pharmacokinetics in volunteers, and the only forensic case published that we found associates AM-1220 with two other synthetic agonists (MAM-2201 and AM-2232), which rules out attributing causality to it alone.
Key sources.
- Marusich JA et al., Finding order in chemical chaos: continuing characterization of synthetic cannabinoid receptor agonists, Neuropharmacology 2018: CB1/CB2 affinity, [35S]GTPγS and THC substitution for AM-1220 (new tab)PMID 29113898
- Andersen HK et al., Molecular signaling of synthetic cannabinoids: comparison of CB1 receptor and TRPV1 channel activation, Eur J Pharmacol 2021: activation of the TRPV1 channel by AM-1220 (new tab)PMID 34224700
- Watanabe S, Kuzhiumparambil U, Fu S, Forensic Toxicol 2018: in vitro metabolism of AM1220 (human liver microsomes, Cunninghamella elegans) (new tab)PMID 29963209
- Zaitsu K et al., Int J Legal Med 2015 (erratum 2016, PMID 26718839): determination by LC/Q-TOFMS of MAM-2201, AM-1220 and AM-2232 in post-mortem plasma and urine (new tab)PMID 26349566
- Deng H et al., J Med Chem 2005: cannabinergic indole analogues (AM-2233 series); values for AM-1220 at rat CB1 and mouse CB2 read in ChEMBL (new tab)PMID 16190764
- Langer N et al., Drug Test Anal 2014: identification and quantification of synthetic agonists in « spice »-type mixtures in Germany (autumn 2012) (new tab)PMID 23723183
- D'Ambra TE et al., C-Attached aminoalkylindoles: potent cannabinoid mimetics, Bioorg Med Chem Lett 1996;6:17-22 (new tab)DOI 10.1016/0960-894X(95)00560-G
- Kneisel S et al., Identification of the cannabimimetic AM-1220 and its azepane isomer in a research chemical and several herbal mixtures, Forensic Toxicol 2012;30:126-134 (new tab)DOI 10.1007/s11419-012-0137-6
- Uchiyama N et al., Identification of two new-type synthetic cannabinoids (APICA, APINACA) and detection of five synthetic cannabinoids, including AM-1220 and AM-1248, in illegal products, Forensic Toxicol 2012;30:114-125 (new tab)DOI 10.1007/s11419-012-0136-7
- ANSM, consolidated list of substances classified as narcotics, updated 16 February 2026 (annex IV, « indol-3-yl methanone » family, AM-1220 cited as an example) (new tab)
- Order of 31 March 2017 amending the order of 22 February 1990: « indol-3-yl methanone » family of annex IV (Légifrance, JORF of 6 April 2017) (new tab)
- INCB, Green List of psychotropic substances under international control, 36th edition, 2025: AM-1220 is not listed (AM-2201 and JWH-018 are) (new tab)
- ChEMBL CHEMBL68641 (AM-1220): measured activities and source publications (new tab)
History
- Source
- Laboratory. No natural occurrence: a molecule arising from pharmaceutical research, diverted to the market for smokable herbal mixtures, where it is sprayed onto dried plant material sold under fanciful names. It was identified in 2012 in a « research chemical » bought online and in illegal products in Japan (Kneisel et al., 2012; Uchiyama et al., 2012), then in German herbal mixtures analysed in the autumn of 2012 (Langer et al., 2014).
Origin
Laboratory synthesis
No biosynthetic pathway: AM-1220 exists neither in hemp nor in any living organism. It is obtained by wholly synthetic means, within the aminoalkylindole chemical class. Described here by chemical class only.
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. It does not appear in the schedules of the 1971 Convention on Psychotropic Substances (green list of the INCB, 35th and 36th editions). France cites this molecule by name in annex IV of its list.
- France
A narcotic in France, but through a generic family, with a mention as an example. AM-1220 is cited (« notamment ») in the ANSM consolidated list (updated 16 February 2026), in annex IV, under the generic family of the « indol-3-yl methanones »: a substituent on the nitrogen of the indole ring of the alkyl, haloalkyl, cycloalkylmethyl, 1-(N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl type, and a naphthyl, benzyl, phenyl, cyclopropyl or adamantyl group on the carbon of the methanone bridge. AM-1220, which bears a 1-(N-methylpiperidin-2-yl)methyl on the nitrogen and a naphthyl on the methanone bridge, meets this definition. The « indol-3-yl methanone » family was introduced into annex IV by the decree of 31 March 2017 (JORF of 6 April 2017); according to a reading of the decree of 3 October 2017 (JORF of 10 October 2017), which replaces the text of annex IV, AM-1220 was added to this list of examples on that date (it does not appear in the text of the decree of 31 March 2017). Possession, transfer and use fall under the criminal regime for narcotics.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Synthetic CB receptor agonist › New psychoactive substance
- Class
naphthoylindole
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Marusich JA et al., Finding order in chemical chaos: continuing characterization of synthetic cannabinoid receptor agonists, Neuropharmacology 2018: CB1/CB2 affinity, [35S]GTPγS and THC substitution for AM-1220 (new tab)PMID 29113898
- Andersen HK et al., Molecular signaling of synthetic cannabinoids: comparison of CB1 receptor and TRPV1 channel activation, Eur J Pharmacol 2021: activation of the TRPV1 channel by AM-1220 (new tab)PMID 34224700
- Watanabe S, Kuzhiumparambil U, Fu S, Forensic Toxicol 2018: in vitro metabolism of AM1220 (human liver microsomes, Cunninghamella elegans) (new tab)PMID 29963209
- Zaitsu K et al., Int J Legal Med 2015 (erratum 2016, PMID 26718839): determination by LC/Q-TOFMS of MAM-2201, AM-1220 and AM-2232 in post-mortem plasma and urine (new tab)PMID 26349566
- Deng H et al., J Med Chem 2005: cannabinergic indole analogues (AM-2233 series); values for AM-1220 at rat CB1 and mouse CB2 read in ChEMBL (new tab)PMID 16190764
- Langer N et al., Drug Test Anal 2014: identification and quantification of synthetic agonists in « spice »-type mixtures in Germany (autumn 2012) (new tab)PMID 23723183
- D'Ambra TE et al., C-Attached aminoalkylindoles: potent cannabinoid mimetics, Bioorg Med Chem Lett 1996;6:17-22 (new tab)DOI 10.1016/0960-894X(95)00560-G
- Kneisel S et al., Identification of the cannabimimetic AM-1220 and its azepane isomer in a research chemical and several herbal mixtures, Forensic Toxicol 2012;30:126-134 (new tab)DOI 10.1007/s11419-012-0137-6
- Uchiyama N et al., Identification of two new-type synthetic cannabinoids (APICA, APINACA) and detection of five synthetic cannabinoids, including AM-1220 and AM-1248, in illegal products, Forensic Toxicol 2012;30:114-125 (new tab)DOI 10.1007/s11419-012-0136-7
- ANSM, consolidated list of substances classified as narcotics, updated 16 February 2026 (annex IV, « indol-3-yl methanone » family, AM-1220 cited as an example) (new tab)
- Order of 31 March 2017 amending the order of 22 February 1990: « indol-3-yl methanone » family of annex IV (Légifrance, JORF of 6 April 2017) (new tab)
- INCB, Green List of psychotropic substances under international control, 36th edition, 2025: AM-1220 is not listed (AM-2201 and JWH-018 are) (new tab)
- ChEMBL CHEMBL68641 (AM-1220): measured activities and source publications (new tab)
Identifiers
Names
- IUPAC name
- [1-[(1-methylpiperidin-2-yl)methyl]indol-3-yl]-naphthalen-1-ylmethanone
- Other names
- AM1220 · AM 1220 · (±)-AM-1220 · CHEMBL68641
Identifiers
- Formula
- C₂₆H₂₆N₂O
- CAS
- 137642-54-7
- PubChem CID
- 9929889(new tab)
- InChIKey
- URKVBEKZCMUTQC-UHFFFAOYSA-N
- SMILES
- CN1CCCCC1CN2C=
C(C3= CC= CC= C32) C(= O) C4= CC= CC5= CC= CC= C54
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.